Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 16.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,171 shares of the company’s stock after selling 7,802 shares during the period. BNP Paribas Financial Markets owned 0.09% of Omnicell worth $1,751,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Millrace Asset Group Inc. bought a new stake in Omnicell during the third quarter worth approximately $1,223,000. The Manufacturers Life Insurance Company raised its stake in shares of Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock worth $1,102,000 after buying an additional 1,813 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Omnicell by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after buying an additional 22,198 shares during the period. Intech Investment Management LLC bought a new position in Omnicell during the third quarter valued at about $753,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Omnicell by 750.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after acquiring an additional 259,463 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays upped their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, Bank of America restated a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Stock Down 0.1 %

Shares of NASDAQ:OMCL opened at $46.00 on Friday. The company’s fifty day moving average is $44.90 and its two-hundred day moving average is $38.54. The company has a market cap of $2.13 billion, a P/E ratio of -117.95, a price-to-earnings-growth ratio of 34.89 and a beta of 0.77. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.